X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Russia authorises use of single-dose Covid-19 vaccine Sputnik Light

Content Team by Content Team
11th May 2021
in News
Russia authorises use of single-dose Covid-19 vaccine Sputnik Light

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF) have announced the Russian Ministry of Health’s authorisation for single-dose Covid-19 vaccine Sputnik Light for use in the country.

Sputnik Light, which is based on the human adenoviral vector platform, is the first component, a recombinant human adenovirus serotype number 26 (rAd26), of the Sputnik V Covid-19 vaccine.

Sputnik V has received authorisation in several countries. According to the data, the Sputnik Light vaccine showed an efficacy of 79.4% 28 days after administering the shot.

RDIF noted that such an efficacy level (near 80%) is greater than that of most of the existing two-dose vaccines.

To calculate the efficacy rate, data from Russians who received only a single dose during the mass vaccination programme conducted between 5 December last year and 15 April this year were obtained.

The infection rate from the 28th day after receiving the vaccine in subjects was only 0.277% while among the unvaccinated people it was 1.349%.

Phase I/II Safety and Immunogenicity study of the Sputnik Light vaccine began in January this year with interim results reported on 10 March. The results showed that Sputnik Light could stimulate antigen-specific IgG antibody development in 96.9% of subjects 28 days after vaccination.

Sputnik Light was found to be safe with 91.67% of subjects developing virus-neutralising antibodies during this time period.

RDIF CEO Kirill Dmitriev said: “The Sputnik Light vaccine significantly reduces the possibility of severe cases leading to hospitalisation, with only one injection needed.

“The characteristics of the vaccine provide for simple storage and logistics, while Sputnik Light has an affordable price of less than $10.”

In another development, Novavax concluded an advance purchase agreement with Gavi, the Vaccine Alliance, to deliver its recombinant protein-based Covid-19 vaccine candidate NVX-CoV2373 to the COVAX Facility.

According to the deal, Novavax will produce and market 350 million doses of the vaccine to the countries participating under the COVAX Facility. Earlier, Novavax reported that the Covid-19 vaccine NVX-CoV2373 offered cross-protection against the B.1.351 variant in the Phase IIb trial in South Africa.

Previous Post

Yangtze River Pharmaceutical Group Selects TraceLink Platform for Global Compliance

Next Post

Vectura and Inspira Pharmaceuticals Sign Agreement to Develop Potential Inhaled Treatment for COVID-19

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
Vectura and Inspira Pharmaceuticals Sign Agreement to Develop Potential Inhaled Treatment for COVID-19

Vectura and Inspira Pharmaceuticals Sign Agreement to Develop Potential Inhaled Treatment for COVID-19

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In